Skip to main content
    P

    PepGen Ltd (PEPG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.47
    +0.15 (+6.47%)

    Market Cap: $169.47M

    Last updated: Nov 06, 2026 at 4:40 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(12/18)
    Avg Surprise
    -11.58%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.27
    Range$-0.29 - $-0.26
    6 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.28+0.6%
    60d ago$-0.27-2.5%
    30d ago$-0.27-2.5%
    7d ago$-0.27-2.5%
    Current$-0.27
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.23
    Range$-0.46 - $-0.15
    6 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    Last 12 of 20 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.23$-0.46 - $-0.15--6--
    Sep 26EST
    		-$-0.27$-0.29 - $-0.26--6
    0
    1
    30d
    		-
    Jun 26
    Reported Aug 6
    		$-0.26$-0.30$-0.37 - $-0.26+13.33%Beat7
    3
    1
    30d
    		+62.9%
    Mar 26
    Reported May 12
    		$-0.26$-0.35$-0.40 - $-0.27+26.01%Beat4
    2
    0
    30d
    		+72.1%
    Dec 25
    Reported Mar 4
    		$-0.27$-0.39$-0.50 - $-0.22+30.77%Beat5
    3
    1
    30d
    		+60.3%
    Sep 25
    Reported Nov 12
    		$-0.52$-0.56$-0.72 - $-0.24+7.14%Beat4
    2
    1
    30d
    		+21.2%
    Jun 25
    Reported Aug 7
    		$-0.70$-0.85$-0.92 - $-0.71+17.65%Beat2
    No revisions (30d)
    		+19.5%
    Mar 25
    Reported May 8
    		$-0.92$-0.75$-0.75 - $-0.75-22.67%Miss1
    No revisions (30d)
    		-46.0%
    Dec 24
    Reported Feb 24
    		$-0.68$-0.81$-0.82 - $-0.62+16.05%Beat2
    1
    0
    30d
    		+16.0%
    Sep 24
    Reported Nov 7
    		$-0.66$-0.77$-0.98 - $-0.64+14.29%Beat5
    No revisions (30d)
    		+32.7%
    Jun 24
    Reported Aug 8
    		$-0.87$-0.68$-0.85 - $-0.66-27.94%Miss5
    No revisions (30d)
    		-6.1%
    Mar 24
    Reported May 14
    		$-0.63$-0.64$-0.85 - $-0.64+1.56%Beat5
    No revisions (30d)
    		+8.7%
    Dec 23
    Reported Mar 6
    		$-0.81$-1.01$-1.19 - $-0.72+19.80%Beat5
    No revisions (30d)
    		-237.5%
    Sep 23
    Reported Nov 8
    		$-0.98$-0.80$-1.06 - $-0.71-22.50%Miss5
    No revisions (30d)
    		-24.1%

    Key Metrics

    Valuation
    P/E Ratio-1.89EV/EBITDAN/A
    Price/FCF-2.46xFCF Yield-40.64%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-75.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio13.36xQuick Ratio13.36x
    Trading Statistics
    Beta2.02Avg Volume1.04M
    52-Week High$7.8052-Week Low$1.31

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.44
    SMA 20$2.52
    SMA 50$2.67
    SMA 200$2.96
    EMA 10$2.45
    EMA 20$2.50
    EMA 50$2.56
    EMA 200$2.78

    MACD

    Line: -0.06Signal: -0.05Hist: -0.01

    ADX

    ADX: 12.5+DI: 18.5-DI: 20.6

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down96.0
    PSAR$2.75

    Bollinger Bands

    Upper Band$2.81
    Lower Band$2.23
    %B Position2304%(Upper)
    Band Width0.41

    RSI (14-Day)

    Neutral
    48.0

    Momentum Oscillators

    Stoch %K25.1
    Stoch %D25.3
    Williams %R-67.5
    ROC (10d)-2.0%
    Momentum-0.05
    CCI (20d)-57.5
    MFI (14d)50.9

    Volatility Measures

    ATR (14d)$0.22(8.8%)
    StdDev (20d)0.15
    Hist Vol76.3%(High)

    Volume Flow

    VWAP$2.44
    OBV141.0M
    AD Line69.4M
    CMF (20d)-0.050

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio0.9x
    VWMA (20d)$2.56

    Pivot Points

    R3$2.84
    R2$2.69
    R1$2.51
    Pivot Point$2.36
    S1$2.18
    S2$2.03
    S3$1.85

    Advanced Oscillators

    TSI-8.28
    Ultimate Osc40.5
    KST-51.80

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.49M$0$0$0$1.66M$0
    Cost of Revenue$0$0$1.06M$0$0$0$380,000$0$0$0$354,000$0
    Gross Profit$0$0$-1,058,000$0$0$0$-380,000$0$0$0$-354,000$0
    Operating Expenses$18.94M$18.94M$19.70M$18.65M$23.93M$31.32M$24.34M$23.17M$30.43M$19.80M$20.81M$24.78M
    R&D$12.52M$13.00M$13.85M$13.42M$18.39M$25.38M$18.96M$17.72M$25.06M$14.73M$16.30M$20.54M
    SG&A$6.42M$5.94M$5.85M$5.23M$5.54M$5.94M$5.38M$5.45M$5.36M$5.07M$4.51M$4.24M
    Operating Income$-18,939,000$-18,942,000$-19,705,000$-18,654,000$-23,932,000$-31,321,000$-24,345,000$-23,171,000$-30,425,000$-19,798,000$-20,811,000$-24,780,000
    Interest Income$1.09M$1.25M$1.42M$634,000$842,000$1.12M$1.46M$1.83M$2.12M$1.74M$1.35M$1.58M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-17,796,000$-17,748,000$-18,291,000$-18,026,000$-23,087,000$-30,202,000$-22,859,000$-21,384,000$-28,335,000$-18,020,000$-19,422,000$-23,290,000
    Income Tax Expense$16,000$15,000$0$0$0$0$0$0$0$0$0$0
    Net Income$-17,812,000$-17,763,000$-18,340,000$-18,026,000$-23,087,000$-30,202,000$-22,242,000$-21,384,000$-28,335,000$-18,020,000$-19,495,000$-23,290,000
    EBITDA$-18,591,000$-18,564,000$-20,649,000$-17,384,000$-23,112,000$-30,695,000$-26,927,000$-21,894,000$-27,561,000$-20,030,000$-20,756,000$-24,614,000
    EBIT$-18,889,000$-18,998,000$-19,710,000$-18,660,000$-23,929,000$-31,324,000$-24,319,000$-23,210,000$-30,456,000$-19,755,000$-20,768,000$-24,868,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PEPG

    PEPG Valuation and Fair Value

    P/E
    -1.9x
    P/FCF
    -2.5x
    P/B
    1.4x
    See GNG's fair value

    PEPG Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -75.4%
    FCF yield
    -40.6%

    PEPG Competitors

    CompanyTicker
    Whitehawk Therapeutics, Inc.WHWK
    Zentalis Pharmaceuticals LlcZNTL
    Invivyd Inc.IVVD
    Niagen Bioscience, Inc.NAGE
    Upstream Bio, Inc.UPB
    OPTIMIZERx CorpOPRX
    Entrada Therapeutics IncTRDA
    EDAP TMS SAEDAP

    Sector: Healthcare

    PEPG Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    0
    Buy
    7
    Hold
    0
    Sell
    0
    Strong Sell
    1

    PEPG Bull Case vs Bear Case

    Bull case

    • PEPG beat EPS estimates in 87.5% of its last 8 reported quarters.
    • 87.5% of PEPG's analyst ratings are Buy or Strong Buy.

    PEPG Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    12.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.27
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    PEPG Earnings Date

    PEPG reports Nov 10, 2026. The date is estimated.

    PEPG ETF Holders

    GNG tracks 4 ETFs that hold PEPG. The largest weights:

    1. iShares Biotechnology ETF (IBB), 0.01% of the fund
    2. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    3. Vanguard Morningstar Total Stock Market ETF (VTI), <0.01% of the fund
    4. Vanguard Extended Market Index Fund ETF Shares (VXF), <0.01% of the fund
    Open the ETF Stock Exposure tool for PEPG

    See insider activity

    Frequently Asked Questions About PEPG

    When does PEPG report earnings?

    PepGen Ltd (PEPG) is expected to report earnings on Nov 10, 2026.

    Does PEPG pay dividends?

    PepGen Ltd (PEPG) does not currently pay a regular dividend.

    What is PEPG's market cap?

    PepGen Ltd (PEPG) has a market capitalization of $169.47M with a current stock price of $2.47.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In